Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Shares of Elanco Animal Health Are Skyrocketing - Can This Trend Continue?

Elanco Animal Health stock is trading -6.29% below its average target price of $23.82 after marking a 3.9% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $18.0 to $27.0 per share.

Elanco Animal Health has an average level of shares sold short, at 6.9% of its total share float. The stock's short ratio (also called days to cover) is 4.5. The company's insiders own 1.05% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 111.0% of Elanco Animal Health's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Elanco Animal Health

Date Reported Holder Percentage Shares Value
2025-06-30 Dodge & Cox Inc 17% 82,895,232 $1,850,221,552
2025-06-30 FMR, LLC 13% 64,883,397 $1,448,197,401
2025-06-30 Primecap Management Company 10% 51,766,814 $1,155,435,272
2025-09-30 Vanguard Group Inc 10% 48,586,708 $1,084,455,307
2025-06-30 Blackrock Inc. 5% 23,071,471 $514,955,225
2025-06-30 Dimensional Fund Advisors LP 5% 22,746,400 $507,699,641
2025-06-30 T. Rowe Price Investment Management, Inc. 4% 19,554,942 $436,466,299
2025-06-30 Black Creek Investment Management Inc. 4% 19,250,840 $429,678,742
2025-06-30 Citadel Advisors Llc 3% 13,700,781 $305,801,427
2025-06-30 UBS Group AG 2% 10,506,691 $234,509,339
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS